CTLA4 and neoplasm: Using the CT1BA5 tumor model, we show that ecDNA tumors are immunologically “cold”, exhibiting poor lymphocyte infiltration and being refractory to anti-PDL1 or anti-CTLA4 immune checkpoint blockade therapies.